Abstract:Wilson disease (WD) is an autosomal recessive disorder of copper metabolism caused by mutations in the ATP7B gene, which leads to copper accumulation in various organs and predominantly presents with hepatic or neuropsychiatric symptoms [1]. Chelation therapy is central, and liver transplant (LT) is the only option if it fails [2]. Both orthotopic liver transplantation (OLT) and livingdonor liver transplantation (LDLT) are acceptable [3–6]. We administered a low-copper diet and zinc monotherapy to 8 postLT patients with WD and followed each for 3 to 9 years in order to explore the necessity of a low-copper diet and zinc monotherapy after LT as well as chelation therapy for post-LT patients with neurological deterioration. Our study was approved by the ethics committees of Huashan Hospital and First Affiliated Hospital of Fujian Medical University. The diagnosis was based on clinical manifestations and ATP7B mutation analysis using a procedure previously described [7]. Patients 1, 6, 7 received LT due to decompensated liver cirrhosis and patients 2, 3, 5 did due to fulminant liver failure. Patients 4, 8 had mild liver dysfunction, but received LT for disabling neurological symptoms. Patients 1, 3, 4, 5 received LT right after they were diagnosed. Patients 2, 6, 7, 8 were treated with penicillamine combined with zinc for 6–12 months prior to LT but responded poorly. Patient 7 received LDLT with her mother as the donor and the other patients received OLT. The surgery was successful for each patient. Tacrolimus was administered for immunosuppression. One month after LT, we gave the patients 140 mg of zinc gluconate three times a day, separated from food by at least 1 h. The patients were also asked to avoid food rich in copper contents [8]. Patients were followed up by two senior neurologists. Laboratory data were collected monthly after LT for 1 year, yearly for 2 years and every 2 years afterward. The genotype, clinical manifestations and follow-up data are shown in Table 1. Chromatograms of ATP7B sequencing results are shown in Figure 1. For the eight patients, the ceruloplasmin levels returned to normal 1 month after LT and liver functions tests within 1 year after LT. Urinary copper levels were measured in 4 of 8 patients, which decreased but still higher than normal. Three patients (patient 3, 5, and 6) with good compliance had normal liver function test results and abdominal ultrasound findings ever since. Another three patients (patients 1, 2, and 7) with poor compliance presented different symptoms. The neurological symptoms of patients 4 and 8 worsened despite successful LT. Patient 1 was admitted for jaundice and edema 2 years after LT. He was scaled as Child-Pugh level A with total bilirubin 26.3 umol/L. Liver cirrhosis and splenomegaly were detected by ultrasonography. Liver biopsy suggested chronic cell rejection. The blood concentration of tacrolimus was 6.59 ng/mL,within the recommended range [9]. Plasma copper level was normal (13.8 lmol/L; normal range: 12.7–30.2 lmol/L), but ceruloplasmin level was low (0.15 g/L; normal range: 0.2–0.4 g/L) and 24-h urinary copper excretion was elevated (232 lg/24 h; normal range: <100 lg/24 h), thus disrupted copper metabolism was suspected. 125 mg of D-penicillamine three times a day and 280 mg of zinc gluconate was administered. Jaundice was resolved and liver functions tests were normal 3 months later, so D-penicillamine was tapered off. Our recommended therapy was started. The

Relapse following withdrawal of D‐penicillamine from combination (D‐penicillamine + zinc) therapy in hepatic Wilson disease

[Treatment of Wilson's Disease with Penicillamine and Zinc Salts: a Follow-Up Study].

Efficacy and safety of D-penicillamine, trientine, and zinc in pediatric Wilson disease patients

Comparison of the Effectiveness and Safety of D-Penicillamine and Zinc Salt Treatment for Symptomatic Wilson Disease: A Systematic Review and Meta‐Analysis

Safety profile of D-penicillamine: a comprehensive pharmacovigilance analysis by FDA adverse event reporting system

Probing and gauging of D-Penicillamine xenobiotics in hepatic Wilson disease patients

Population Screening and Diagnostic Strategies in Screening Family Members of Wilson’s Disease Patients

Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets

Effect of Decoppering Therapy on Immune Function in Wilson's Disease

Clinical characteristics and prognosis of early diagnosed Wilson's disease: A large cohort study

Zinc monotherapy and a low-copper diet are beneficial in patients with Wilson disease after liver transplantation.

Kidney complications of Wilson disease and its treatments: A case report and literature review

Clinical and laboratory profile and outcome in children with Wilson disease: an observational study in South India

The level of serum lipids, vitamin E and low density lipoprotein oxidation in Wilson's disease patients

Single Pass Albumin Dialysis and Plasma Exchange for Copper Toxicity in Acute Wilson Disease

Zinc Mono-Therapy in Pre-Symptomatic Chinese Children with Wilson Disease: a Single Center, Retrospective Study.

Risk factors of significant relapse and appropriate maintenance therapy strategy in SLE-associated immune thrombocytopenia

Successful treatment of acute liver failure due to Wilson's disease: Serendipity or fortuity?

An 18-year follow-up of a case of D-penicillamine-induced Elastosis perforans serpiginosa

Pediatric Wilson Disease Presenting As Acute Liver Failure: Prognostic Indices.